Therapeutics News and Research

RSS

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Lipid molecule fuels cancer growth

Cancer cells seldom start off stealthy. Quite to the contrary, they announce their presence to the immune system by planting chemical red flags right on their membranes. Once alerted, the body's defenses can swoop in, destroying rogue cells before they can do much damage. Lying at the heart of this early warning system are lipids, fatty compounds previously seen by cancer biologists primarily as a fuel source for burgeoning tumors.

18 Sep 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Cardiovascular risks of COVID-19 antivirals

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful consideration when prescribing these drugs to high-risk patients.

16 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024

NIH funds new research to combat emerging viruses

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID's new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

14 Sep 2024

New research network focuses on high-priority viruses

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises-;both in the United States and around the world. NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately $100 million per year to fund the program, pending the availability of funds.

14 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

AI-powered treatment allocation improves public health outcomes

A new study sheds light on a promising approach using machine learning to more effectively allocate medical treatments during a pandemic or any time there's a shortage of therapeutics.

14 Sep 2024

Scientists develop novel technique to combat T cell exhaustion

Fighting cancer is exhausting for T cells. Hostile tumor microenvironments can drain their mitochondrial activity, leading to a condition known as T cell exhaustion. This phenomenon also hinders adoptive cell therapies, in which healthy, tumor-targeting T cells are infused into patients with cancer. A novel method to boost mitochondrial activity and charge up T cells is needed.

14 Sep 2024

Study reveals how SARS-CoV-2 triggers diabetes by destroying pancreatic cells

Researchers from Weill Cornell Medicine have used a cutting-edge model system to uncover the mechanism by which SARS-CoV-2, the virus that causes COVID-19, induces new cases of diabetes, and worsens complications in people who already have it.

13 Sep 2024

Breakthrough study sheds light on mechanisms behind the spread of gastric cancer to the peritoneum

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to 770,000 deaths each year.

13 Sep 2024

New mechanism aims to ensure equitable distribution of mpox vaccines and treatments

In coordination with Member States, the World Health Organization (WHO) and partners have established an access and allocation mechanism for mpox medical countermeasures including vaccines, treatments and diagnostic tests.

13 Sep 2024

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.

13 Sep 2024

Significant global cardiovascular risk linked to high lipoprotein(a) levels

Review in The Lancet finds that one in five globally are at risk of contracting cardiovascular diseases, because they carry a genetic risk of high levels of a specific lipoprotein, which can be tested for and possibly treated.

12 Sep 2024

Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

12 Sep 2024

High-dose amphetamine use linked to increased risk of psychosis or mania

Prescribing rates for stimulants that treat attention-deficit/hyperactivity disorder (ADHD) have increased significantly over the past decade, with some of the largest increases reported during the COVID-19 pandemic.

12 Sep 2024

Study links protein increases to cognitive improvement in Alzheimer's

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques.

11 Sep 2024

MSK researchers identify a new, rare type of small cell lung cancer

A team of doctors and researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked.

11 Sep 2024

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard's Office of Technology Development (OTD) and Boston University (BU)'s Technology Development office for novel molecules that activate the lymphatic system - a first in the pharma industry.

11 Sep 2024